Granulocyte colony-stimulating factors: finding the right indication.

Publication Type:

Journal Article


Current opinion in oncology, Volume 19, Issue 4, p.299-307 (2007)


Antineoplastic Agents, Colony-Stimulating Factors, Evidence-Based Medicine, Granulocyte Colony-Stimulating Factor, Humans, Intercellular Signaling Peptides and Proteins, Neoplasms, NEUTROPENIA, Practice Guidelines as Topic, Recombinant Proteins, Risk Factors


Neutropenic complications including febrile neutropenia represent major dose-limiting toxicities of cancer chemotherapy. Recommendations for the use of recombinant myeloid growth factors to reduce the risk of neutropenic complications and sustain dose intensity continue to evolve.